Clinical Trial

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Name: A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer — clinical trial record (NCT07673029)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study is designed to compare efficacy and safety of GQ1005 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.

Trial Details

NCT Number	NCT07673029
Lead Sponsor	GeneQuantum Healthcare (Suzhou) Co., Ltd.
Conditions	HER2-positive Breast Cancer
Enrollment	228 participants
Start Date	2025-01-10
Primary Completion	2027-01-09 (estimated)
Study Completion	2028-01-09 (estimated)
Updated on ClinicalTrials.gov	2026-06-29